Merck lawyers say that evidence that surfaced in a recent New Orleans trial illustrates why the company wants to try each of the thousands of Vioxx cases on its own. "Each involves specific facts. It's hard to support generalizations," attorney Phil Beck says. In the latest case, it came out at trial that the 64-year-old plaintiff stopped taking the drug four days before the heart attack, and hospital film revealed the blockage in the plaintiff's artery was almost all plaque, rather than a large blood clot.
November 17, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Evidence brought out at trial in the 11th case alleging that Merck & Co. covered up dangers of its painkiller Vioxx shows just why the company wants to try each of the thousands of lawsuits on its own, company attorneys say.
“Each involves specific facts. It’s hard to support generalizations,” attorney Phil Beck says.
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
McCarter & English, LLP is seeking litigation attorneys for our Newark, NJ offices. Candidates must have 3-6 years of law firm experien...
McCarter & English, LLP is actively seeking a corporate associate for its office located in Boston, MA. Candidate must have 2 - 5 years ...
McCarter & English, LLP is actively seeking a midlevel insurance coverage associate for its Newark, NJ and/or Philadelphia, PA offices. ...
